Cargando…

Treatment of Down Syndrome-Associated Arthritis with JAK Inhibition

Down syndrome (DS) results from a trisomy of chromosome 21, which causes immune dysregulation that leads to hyperactivation of interferon and Janus kinase (JAK) signaling. This results in complex medical abnormalities in the immune system and an increase in autoimmune and autoinflammatory conditions...

Descripción completa

Detalles Bibliográficos
Autor principal:	Jones, Jordan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308516/ https://www.ncbi.nlm.nih.gov/pubmed/35879952 http://dx.doi.org/10.1155/2022/4889102

Ejemplares similares

JAK inhibition for treatment of psoriatic arthritis in Down syndrome
por: Pham, Andrew T., et al.
Publicado: (2021)

Assessment of Down Syndrome-Associated Arthritis: A Survey of Down Syndrome Clinic Providers
por: Jones, Jordan T., et al.
Publicado: (2021)

Atypical Presentation of Systemic Arthritis in a Toddler with Down Syndrome
por: Worley, Emily, et al.
Publicado: (2021)

Brief Musculoskeletal Screen and Patient Education for Down Syndrome-Associated Arthritis
por: Jones, Jordan T., et al.
Publicado: (2021)

Down Syndrome-Associated Arthritis (DA): Diagnostic and Management Challenges
por: Jones, Jordan T, et al.
Publicado: (2022)

Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists
por: Nicek, Anna, et al.
Publicado: (2020)

Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
por: Galbraith, Matthew D., et al.
Publicado: (2023)

Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report
por: Pannell, N, et al.
Publicado: (2021)

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core
por: Grimm, Juliane, et al.
Publicado: (2022)

Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy
por: Wu, Jianqiang, et al.
Publicado: (2023)

Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
por: Mehta, Puja, et al.
Publicado: (2020)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome
por: Boyadzhiev, M., et al.
Publicado: (2019)

Management of Enteritis Associated With Tricohepatoenteric Syndrome due to SKIV2L Mutation Using the Combination of JAK1/2 Inhibition and Azathioprine
por: Talbot, Jonathan, et al.
Publicado: (2022)

Two Rare Variants of Down Syndrome: Down-Turner Syndrome and Down Syndrome with Translocation (13;14): A Case Report
por: GUMUS, Evren
Publicado: (2019)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
por: Migita, Rioko, et al.
Publicado: (2022)

Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
por: Rachubinski, Angela L., et al.
Publicado: (2019)

Type 2 diabetes mellitus: An unusual association with Down's syndrome
por: Kota, Sunil Kumar, et al.
Publicado: (2013)

Congenital duodenal obstruction associated with Down's syndrome presenting with hematemesis
por: Al Shahwani, Noora, et al.
Publicado: (2013)

Bowel-associated dermatosis-arthritis syndrome (BADAS) in a patient with cystic fibrosis
por: Rosen, Jordan D., et al.
Publicado: (2018)

Combination Therapy With Pulmonary Vasodilatation and JAK2 Inhibition for Pulmonary Hypertension With Polycythemia Vera
por: Momose, Riichi, et al.
Publicado: (2022)

Neurofibromatosis, Down's syndrome, and acquired abnormalities
por: Ali, Syed Yousuf, et al.
Publicado: (2016)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

The Ponseti Method for the Treatment of Clubfeet Associated with Down Syndrome
por: Portalatin, Edwin, et al.
Publicado: (2022)

A modified presurgical alveolar molding technique for treatment of cleft in Down syndrome
por: Gonca, Merve, et al.
Publicado: (2021)

Deep sedation for dental treatment in a Down syndrome patient with Eisenmenger syndrome: A case report
por: Chi, Seong In, et al.
Publicado: (2016)

Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice
por: Llop-Guevara, Alba, et al.
Publicado: (2015)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021)

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
por: Braun, Theodore P., et al.
Publicado: (2014)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

Arthritis in Down's syndrome is still being missed
por: Cruikshank, M, et al.
Publicado: (2008)

Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis
por: Strauss, Timmy, et al.
Publicado: (2023)

A Male with Cooccurrence of Down Syndrome and Fragile X Syndrome
por: Anderson, Tovi, et al.
Publicado: (2013)

Bilateral Congenital Lacrimal Fistula in Down Syndrome
por: Singh, Manpreet, et al.
Publicado: (2013)

Mosaic double aneuploidy: Down syndrome and XYY
por: Parihar, Mayur, et al.
Publicado: (2013)

Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain
por: Lee, Han-Chung, et al.
Publicado: (2016)

The interplay between inhibition of JAK2 and HSP90
por: Fridman, Jordan S., et al.
Publicado: (2012)

Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
por: Scheinberg, Morton, et al.
Publicado: (2021)

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
por: Ren, Mingyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9hjvh3aff4dtdr0oac7hdtqtm